Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
June 07, 2022 06:30 ET
|
Annexon Biosciences
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month StudyRapid Improvement in Clinical...
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
June 02, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Present Data Highlighting Novel Approach to Treating Complement-Driven Diseases at Upcoming Medical Meetings
June 01, 2022 07:30 ET
|
Annexon Biosciences
BRISBANE, Calif., June 01, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences Highlights Portfolio Progress and Key Anticipated Milestones, and Reports First Quarter 2022 Financial Results
May 09, 2022 16:01 ET
|
Annexon Biosciences
Pioneering Upstream Complement-Targeted Platform with Broad Portfolio of Five Differentiated Product Candidates Anticipating Eight Clinical Catalysts Across Robust Pipeline throughout 2022 and 2023...
Annexon Biosciences to Participate in Upcoming May Investor Conferences
May 05, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., May 05, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical...
Annexon Biosciences Completes Enrollment in ARCHER Phase 2 Trial of Novel C1q Inhibitor, ANX007, in Patients with Geographic Atrophy
April 07, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 04, 2022 06:30 ET
|
Annexon Biosciences
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...
Annexon Biosciences to Present Preclinical Data Supporting Complement Inhibitor Programs for the Treatment of Guillain-Barré Syndrome and Huntington’s Disease at AAN 2022
March 03, 2022 16:01 ET
|
Annexon Biosciences
BRISBANE, Calif., March 03, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients...
Annexon Biosciences Announces Program Highlights and Reports Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 16:01 ET
|
Annexon Biosciences
Multiple Value-Creating Catalysts Across Complement-Targeted Portfolio Anticipated Through 2023 Encouraging Interim Data Reported from Phase 2 Study of ANX005 for Huntington’s Disease; Full Data...
Annexon Biosciences to Participate in the Cowen 42nd Annual Healthcare Conference
February 28, 2022 06:30 ET
|
Annexon Biosciences
BRISBANE, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with...